Axsome Therapeutics, Inc. AXSM
We take great care to ensure that the data presented and summarized in this overview for Axsome Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding AXSM
View all-
Vanguard Group Inc Valley Forge, PA4.18MShares$584 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.3MShares$461 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA1.33MShares$186 Million0.03% of portfolio
-
Rtw Investments, LP New York, NY1.12MShares$156 Million1.82% of portfolio
-
Macquarie Group LTD Australia, C31.08MShares$151 Million0.16% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD1.04MShares$145 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA998KShares$139 Million0.01% of portfolio
-
Invesco Ltd. Atlanta, GA991KShares$138 Million0.02% of portfolio
-
State Street Corp Boston, MA943KShares$132 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT900KShares$126 Million3.45% of portfolio
Latest Institutional Activity in AXSM
Top Purchases
Top Sells
About AXSM
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
Insider Transactions at AXSM
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 04
2025
|
Herriot Tabuteau Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
10,558
-59.36%
|
$1,562,584
$148.18 P/Share
|
|
Dec 04
2025
|
Herriot Tabuteau Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,558
+37.25%
|
$84,464
$8.02 P/Share
|
|
Dec 03
2025
|
Herriot Tabuteau Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
20,163
-73.61%
|
$2,943,798
$146.94 P/Share
|
|
Dec 03
2025
|
Herriot Tabuteau Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,163
+42.4%
|
$161,304
$8.02 P/Share
|
|
Dec 02
2025
|
Herriot Tabuteau Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
49,252
-87.2%
|
$7,092,288
$144.59 P/Share
|
|
Dec 02
2025
|
Herriot Tabuteau Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
49,252
+46.58%
|
$394,016
$8.02 P/Share
|
|
Nov 05
2025
|
Herriot Tabuteau Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
21,775
-75.08%
|
$2,917,850
$134.49 P/Share
|
|
Nov 05
2025
|
Herriot Tabuteau Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
21,775
+42.88%
|
$174,200
$8.02 P/Share
|
|
Nov 04
2025
|
Herriot Tabuteau Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
50,459
-87.47%
|
$6,711,047
$133.79 P/Share
|
|
Nov 04
2025
|
Herriot Tabuteau Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
50,459
+46.66%
|
$403,672
$8.02 P/Share
|
|
Nov 03
2025
|
Herriot Tabuteau Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
91,705
-92.69%
|
$12,105,060
$132.34 P/Share
|
|
Nov 03
2025
|
Herriot Tabuteau Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
91,705
+48.1%
|
$733,640
$8.02 P/Share
|
|
Oct 08
2025
|
Herriot Tabuteau Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
12,774
-63.86%
|
$1,507,332
$118.84 P/Share
|
|
Oct 08
2025
|
Herriot Tabuteau Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,774
+38.97%
|
$102,192
$8.02 P/Share
|
|
Oct 07
2025
|
Herriot Tabuteau Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
13,390
-64.94%
|
$1,580,020
$118.77 P/Share
|
|
Oct 07
2025
|
Herriot Tabuteau Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,390
+39.37%
|
$107,120
$8.02 P/Share
|
|
Oct 06
2025
|
Herriot Tabuteau Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
19,220
-72.67%
|
$2,306,400
$120.17 P/Share
|
|
Oct 06
2025
|
Herriot Tabuteau Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
19,220
+42.09%
|
$153,760
$8.02 P/Share
|
|
Sep 22
2025
|
Mark L. Jacobson Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
10,000
-100.0%
|
$1,150,000
$115.96 P/Share
|
|
Sep 22
2025
|
Mark L. Jacobson Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+50.0%
|
$20,000
$2.85 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 537K shares |
|---|---|
| Open market or private purchase | 1.58K shares |
| Open market or private sale | 654K shares |
|---|